Star Scientific and Altria Group Evolve -- Revenues Stable
The Paragon Report Provides Equity Research on Star Scientific & Altria Group
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/26/11 -- Despite the potential headwinds created by regulatory changes, court cases and healthier consumers, cigarette sales have remained steady, providing steady revenue streams to several of the world's leading cigarette manufacturers. Companies continue to evolve, however, as increasing regulatory pressures have led to a transition into different smokeless tobacco products. The Paragon Report examines investing opportunities in the tobacco industry and provides equity research on Star Scientific, Inc. (NASDAQ: CIGX) and Altria Group, Inc. (NYSE: MO). Access to the full company reports can be found at:
This year the Medical University of South Carolina wants to learn whether a smokeless tobacco product, such as Camel "Snus" leads to quit attempts, smoking reduction and cessation. Researchers are not trying to encourage the use of smokeless tobacco with the study, but are rather trying to provide "objective evidence to guide clinical and regulatory decision-making for this controversial area of tobacco control."
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the tobacco industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
With increasing regulatory pressures and a dwindling customer-base that is growing increasingly aware of smoking's deleterious health effects, companies in the sector are looking to transition into different smokeless tobacco products. Revenue for smokeless products grew 11% in 2010. Some companies, like Star Scientific Inc., are even looking in the direction of health care as a way through the secular shift away from combustible tobacco products.
Star Scientific makes two dissolvable tobacco lozenges, Ariva and Stonewell, which are not subject to Chapter IX of Federal Food Drug & Cosmetic Act. The company recently lost a bid for a new trial in its patent-infringement case against Reynolds American Inc.
Presently Altria offers smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands. Though chewing tobacco has been associated with various oral ailments, it is considered by some to be less hazardous than smoking and isn't as tightly regulated.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2011 - 06:16 Uhr
Sprache: Deutsch
News-ID 1049964
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Investment Services & Trading
Anmerkungen:
Diese Pressemitteilung wurde bisher 70 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Star Scientific and Altria Group Evolve -- Revenues Stable
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
